Targeted next-generation sequencing (Vanderbilt Cancer Panel for MiSeq and MSKCC IMPACT Assay, refer to Supplementary Materials and Methods and Supplementary Tables S5 and S6, and see [32]) did not detect any RAS G12, G13, or Q61 codon mutations (NRAS, KRAS or HRAS) or MEK1/2 (a.k.a. MAP2K1, MAP2K2) mutations in the six pan-negative melanoma cell lines. This evidence concerns the gene KRAS and melanoma.